CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Write off of Deferred Debt Issuance Cost
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) reported Write off of Deferred Debt Issuance Cost of $1.00 million for the 9-month period ending 2016-09-24, per its 10-Q filed 2017-11-09.
Discontinued › Expense Statement › Operating Expenses
us-gaap:WriteOffOfDeferredDebtIssuanceCost · last filed 2018-02-13
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. write off of deferred debt issuance cost for the quarter ending 2016-09-24 was -$400.00K.
| Period end | Write off of Deferred Debt Issuance Cost | Write off of Deferred Debt Issuance Cost as first filed | Write off of Deferred Debt Issuance Cost 3 month | Write off of Deferred Debt Issuance Cost 6 month | Write off of Deferred Debt Issuance Cost 9 month |
|---|---|---|---|---|---|
| 2016-09-24 | -$400.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $1.00M 10-Q · filed 2017-11-09 | |||
| 2016-06-25 | $1.40M 10-Q · filed 2017-08-09 | ||||
| 2016-03-30 | $1.00M 10-K · filed 2018-02-13 | $1.40M 10-Q · filed 2016-11-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |